Today: 20 May 2026
BitMine Immersion (BMNR) stock jumps 15% as Tom Lee pushes 50-billion share authorization vote
4 January 2026
2 mins read

BitMine Immersion (BMNR) stock jumps 15% as Tom Lee pushes 50-billion share authorization vote

NEW YORK, January 4, 2026, 06:51 ET — Market closed

  • BitMine Immersion shares closed up 14.9% on Friday after the company urged holders to back a large increase in authorized shares.
  • The proposal would raise the share cap to 50 billion from 500 million, a filing showed.
  • Investors are watching the Jan. 14 voting deadline and any follow-on capital-raising plans.

BitMine Immersion Technologies Inc shares closed sharply higher in the last U.S. session after the crypto-focused company stepped up its push for shareholders to approve a sweeping increase in its authorized shares. The stock ended Friday up 14.9% at $31.19.

The vote matters because authorized shares set the maximum number of shares a company is allowed to issue under its charter. Raising that ceiling can give management room for stock sales, stock-based deals or stock splits, but it can also amplify dilution worries if new shares are issued.

BitMine’s voting deadline is January 14, and the annual meeting is set for January 15, putting the proposal on a near-term clock. The company has positioned its stock as closely linked to ether, the world’s second-largest cryptocurrency, making any move that touches share count and trading mechanics a focal point for retail and momentum investors.

In a regulatory filing dated Friday, BitMine said it issued a press release encouraging shareholders to vote “FOR” a charter amendment proposal at the upcoming meeting. Sec

The amendment would lift the number of authorized shares to 50 billion from 500 million, according to the filing materials. Authorized shares are not the same as shares outstanding — a company can raise its authorized share count without immediately issuing stock — but the change would expand the company’s capacity to do so.

Chairman Tom Lee framed the proposal primarily as a way to enable future stock splits, which increase the number of shares while lowering the per-share price. “Bitmine’s stock price follows the price of Ethereum,” Lee said in a transcript filed with the SEC. Sec

Lee also pointed to the need for flexibility around capital markets activity and potential acquisitions, according to the transcript. An at-the-market offering, one tool he cited, is a program that allows a company to sell shares into the market over time rather than in one large deal.

BitMine describes itself as a Bitcoin and Ethereum “network company” focused on accumulating crypto for long-term investment, including through mining and capital-raising proceeds, the press release said. It said its operations are located in “low-cost energy regions” including Trinidad and two Texas sites.

The next leg for the shares may hinge as much on macro risk appetite as on company-specific filings. Philadelphia Fed President Anna Paulson said on Saturday that further U.S. interest-rate cuts could take time as policymakers evaluate the economy, according to Reuters — commentary that can sway high-volatility corners of the market, including crypto-linked equities.

Before the next session, investors will be looking to the week’s U.S. data calendar for clues on rates and risk sentiment. The Labor Department is scheduled to release the December employment report on January 9 and the December CPI report on January 13.

Company-specific, the key date remains the January 14 voting deadline ahead of the January 15 annual meeting. Traders will also be alert for any new disclosures about capital-raising plans or an eventual stock split once the vote outcome is known. The Fed’s next policy meeting is scheduled for January 27–28.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Baidu stock today: BIDU jumps on Kunlunxin Hong Kong IPO plan as AI-chip frenzy builds
Previous Story

Baidu stock today: BIDU jumps on Kunlunxin Hong Kong IPO plan as AI-chip frenzy builds

ASX Ltd stock today: shares cling to the low end of the 52-week range as 2026 opens quietly
Next Story

ASX Ltd stock today: shares cling to the low end of the 52-week range as 2026 opens quietly

Go toTop